Investing.com - Verve Therapeutics (NASDAQ: VERV) reported third quarter EPS of $-0.72, $0.18 better than the analyst estimate of $-0.90. Revenue for the quarter came in at $3.12M versus the consensus estimate of $963.67K.
Verve Therapeutics's stock price closed at $14.98. It is down -16.69% in the last 3 months and down -27.21% in the last 12 months.
Verve Therapeutics saw 5 positive EPS revisions and 4 negative EPS revisions in the last 90 days. See Verve Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Verve Therapeutics's Financial Health score is "fair performance".
Check out Verve Therapeutics's recent earnings performance, and Verve Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar